RCC I/II improved survival data

  • 10:54

Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients

Immunicum initiated a phase I/II study in patients with metastasized renal cell cancer in February 2012. The patients were treated with two intratumoral doses of INTUVAX before the primary tumor was surgically removed. Five (5) of the eleven (11) evaluable patients are still alive. Median overall survival for the entire patient population currently stands at about 40 months versus expected 15.2 months (historical data on newly diagnosed patients with metastatic renal cancer treated with the tyrosine kinase inhibitor Sutent/sunitinib). For the group with high-risk prognosis (6 patients), the median overall survival is currently at about 32 months versus expected nine (9) months and for patients with intermediate prognosis (5 patients), the median overall survival is currently at about 45 months versus expected 26 months. The final median overall survival has not yet been reached for any of the three patient groups.